GlassScriptPhysician profile
Whitney Hall Powell
NPI 1619629599
$4,737.32
in general payments reported to CMS, 2019-2025
20 companies · $840 in 2025
The $840 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $479 · 2023: $1,233 · 2024: $1,878 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,950.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $707.45 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $594.98 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $580.24 | 2022-2025 | Cequa, Xelpros |
| Oyster Point Pharma, INC. | $457.43 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $441.44 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $407.11 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $325.00 | 2022-2024 | Kxl System (Not Refurbished), Idose |
| Novartis Pharmaceuticals Corporation | $276.35 | 2021-2023 | |
| Eyevance Pharmaceuticals LLC | $169.05 | 2021-2022 | |
| Sight Sciences, INC. | $140.88 | 2024 | Tearcare System |
| Ocular Therapeutix, INC. | $122.46 | 2024 | Dextenza |
| Horizon Therapeutics Plc | $109.99 | 2023 | Tepezza |
| Harrow Eye, LLC | $101.86 | 2025 | Vevye |
| Alcon Vision LLC | $98.04 | 2022-2025 | Clareon, Tryptyr, Eysuvis |
| Rxsight INC | $54.41 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal), Rxsight Contact Lens |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $48.34 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $45.69 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.90 | 2025 | Ultomiris |
| Dompe US, INC. | $18.71 | 2022 | |
| Thea Pharma INC. | $16.99 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.